Meta-analysis of the diagnostic performance of 18F-FDG PET in renal cell carcinoma

Initial experience with 18F-fluoroethylcholine PET/CT in staging and monitoring therapy response of advanced renal cell carcinoma

“…However, metabolic imaging can provide additional information, especially in the search for metastases. Most experience in PET imaging of RCC has been obtained with 18 F-fluorodeoxyglucose (FDG), for which sensitivities between 47 and 90% and specificities between 80 and 100% were reported for the purpose of staging [3][4][5][6][7]. Apart from 18 F-FDG PET, which revealed a relative high rate of falsenegative primary tumours, numerous non-FDG tracers have been used evaluating renal tumours-11 C-acetate [8,9], only mild 18 F-fluoromisonidazole uptake in RCC [13].…”

Standardized Uptake Values Highly Correlate with Tumor Size and Fuhrman Grade in Patients with Clear Cell Renal Cell Carcinoma

“…first reported the possible value of 18F-FDG PET for the diagnosis of renal cancers in 1991. The reported sensitivities and specificities of 18F-FDG-PET in subsequent studies have generally been suboptimal in comparison to diagnostic CT or MRI, with sensitivities ranging from 40%-94% and specificities ranging from 0%-100% (Kocher et al, 1994;Goldberg et al, 1997;Bachor et al, 1996;Montravers et al, 2000;Ramdave et al, 2001;Miyakita et al, 2002;Aide et al, 2003;Kang et al, 2004;Ak and Can, 2005;Kumar et al, 2005;Martinez et al, 2007). The low sensitivity of 18F-FDG- PET in some reports has been attributed to FDG excretion through the kidneys and collecting systems, decreasing contrast between renal lesions and normal tissues, as well as due to significant variability of 18F-FDG uptake that may be related to variable expression of GLUT-1 glucose transporters, tumor grade, presence of central necrosis, and/or lack of accessibility of 18F-FDG (Bachor et al, 1996;Miyauchi et al, 1996;Montravers et al, 2000;Miyakita et al, 2002;Aide et al, 2003).…”

Primary synovial sarcoma of the kidney: use of PET/CT in diagnosis and follow-up

“…Martinez de Liano et al [8] demonstrated the sensitivity and specifi city of PET/CT in the determination of postoperative restaging and metastatic disease in renal cancers to be 87% and 72%, respectively. They also emphasized that PET/CT is not superior to helical CT for radiological evaluation of the primary disease.…”